Orgenesis Secures $5M Funding to Accelerate Decentralized Cell & Gene Therapy Innovations

We are excited to announce that Orgenesis Inc.

has successfully raised $5,000,000 in its latest funding round, marking another significant milestone in our mission to transform patient care through decentralized cell and gene therapies (CGTs).

Since its inception in 2012, Orgenesis has been at the forefront of biotech innovation, harnessing pioneering technologies to bring groundbreaking therapies to patients across the globe.

This latest infusion of capital will be instrumental in propelling our vision forward, as we continue to develop and scale our uniquely integrated model that bridges academia, hospitals, and industry via our established POCare Network.

Launched in 2020, the POCare Network was designed to make CGTs more accessible and affordable for patients, a commitment that has only grown stronger over time.

In 2022, we further demonstrated our dedication to this cause with the formation of the POCare Services business unit, which focuses on developing and managing our decentralized POCare Centers and proprietary OMPULs.

The funds raised will be strategically deployed to advance our go-to-market efforts, nourish our diverse partnerships, and streamline the development of innovative therapies.

With these investments, we aim to solidify our position as a global leader in decentralized CGTs, ensuring that our advanced therapies reach a broader patient population through a rapid, globally harmonized pathway.

This is an exciting chapter in our journey, as we strive to lower costs while enhancing the scalability and efficiency of our production processes.

We look forward to continuing our collaboration with stakeholders across the healthcare ecosystem to make life-changing therapies available to patients in need, ultimately fulfilling our mission of democratizing access to cutting-edge medical innovations.